Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 4 drugs approved in the U.S. (marked with * below). Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.

        Oncology
        Molecule Name
        Potential Indication
        Phase
        Pre-clinical
        Phase I
        Phase II / POC
        Phase III / Pivotal
        NDA Filed
        Marketed
        Ovarian Cancer (2nd line maintenance) *
        Mainland China, HK & Macau (China)
        Ovarian Cancer (1st line maintenance)*
        Mainland China
        Ovarian Cancer (late line treatment)*
        Gastric Cancer (I/O[3] combo)[1]
        Other solid tumors[2] (I/O[3] combo)
        Glioblastoma (GBM) *
        Hong Kong (China), mainland China
        Mesothelioma* (Optune Lua)
        NSCLC[4]
        Brain Metastases from NSCLC
        Pancreatic Cancer
        Ovarian Cancer
        Gastric Cancer[1]
        Liver Cancer
        GIST[5] (4th Line)*
        GIST[5] (2nd Line)
        B-NHL - r/r FL, r/r DLBCL, r/r MCL, r/r MZL, etc. [6, 7]
        ROS1+ NSCLC[4], NTRK+[8] solid tumors
        HER2+ Breast Cancer
        HER2+ Gastric/GEJ Cancer[9] (combo[10])
        Gastric/GEJ Cancer[9]
        EGFR ex20ins NSCLC
        MET+ NSCLC and GC
        Hepatocellular carcinoma (HCC) (combo with brivanib)
        Melanoma[1]
        Basket trial
        NSCLC[11]
        MSI-high Endometrial[7]
        Multiple tumor types
        Multiple tumor types
        Oncology
        Oncology
        Oncology
        Oncology and autoimmune disease
        No data!
        No data!
        Infectious Disease and Autoimmune
        Molecule Name
        Potential Indication
        Phase
        Pre-clinical
        Phase I
        Phase II / POC
        Phase III / Pivotal
        NDA Filed
        Marketed
        No data!
        No data!
        No data!
        No data!
        No data!
        No data!
        No data!
        No data!
        Acute Bacterial Skin and Skin Structure Infection (ABSSSI) *
        Community-Acquired Bacterial Pneumonia (CABP) *
        A.Baumanii Bacterial Infections
        Generalized Myasthenia Gravis
        Immune Thrombocytopenic Purpura
        PV, CIDP
        Psoriasis, etc.

        Note: [1]  China-only trials;  [2] Including non-small cell lung cancer; [3] Immuno-oncology; [4] Non-small cell lung cancer; [5] Gastrointestinal stromal tumors; [6] B-NHL, B-cell non-Hodgkin lymphoma; r/r, relapsed or refractory; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; [7] Potentially registration-enabling trial; [8] Neurotrophic tropomyosin receptor kinase; [9] Gastroesophageal junction cancer; [10] Phase 2/3 study and registration path in first-line gastric & GEJ cancer; combo with retifanlimab and tebotelimab, respectively; [11] Non-small cell lung cancer; Phase 3 in preparation; [12] Bridging study ongoing.


        万彩吧